{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:15:29Z","timestamp":1783325729862,"version":"3.54.6"},"posted":{"date-parts":[[2026,7,2]]},"group-title":"Genetic and Genomic Medicine","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015326","name":"NIH Common Fund","doi-asserted-by":"crossref","award":["U54NS115052"],"award-info":[{"award-number":["U54NS115052"]}],"id":[{"id":"10.13039\/100015326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine whether boys with VUS detected through Newborn screening (NBS) for Adrenoleukodystrophy (ALD) develop adrenal insufficiency (aiALD) and cerebral ALD (cALD) at rates comparable to those with pathogenic variants, and to evaluate the relationship between C26:0-lysophosphatidylcholine (C26:0-LPC) levels and clinical outcomes.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective multicenter cohort study (2013\u20132025) across six US centers, including 201 males identified through NBS in 19 states. Variants were classified as pathogenic (n=65), likely pathogenic (n=45), or VUS (n=88). Primary outcomes were development of aiALD and cALD; secondary outcomes included C26:0-LPC levels. Statistical analyses included Kaplan\u2013Meier, mixed-effects regression, and Cox models.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    201 males with\n                    <jats:italic>ABCD1<\/jats:italic>\n                    variants identified through NBS for ALD. Median age at last follow-up was 4.2 years (IQR 2.5\u20137.9). Overall, 26% developed aiALD (54% pathogenic, 16% likely pathogenic, 11% VUS), and 8% developed cALD (11%, 9%, and 4.5%, respectively). Pathogenic\/likely pathogenic variants were associated with higher odds of aiALD than VUS (OR 5.8; 95% CI 2.16\u201315.58; p=0.001). At 150 months, 39% of individuals with pathogenic\/likely pathogenic variants remained free of aiALD versus 85% with VUS. C26:0-LPC levels were higher in pathogenic variants and correlated with genotype (p=0.0006). Higher levels were associated with increased aiALD risk and earlier onset (HR 1.38 per 0.1 \u00b5mol\/L; 95% CI 1.20\u20131.59; p&lt;0.0001).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Boys with VUS had lower rates of aiALD and lower C26:0-LPC levels than those with pathogenic variants, although some developed disease. C26:0-LPC correlates with genotype and risk, supporting its role in variant classification and risk-stratified surveillance.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>What\u2019s Known on This Subject<\/jats:title>\n                  <jats:p>Newborn screening for X-linked adrenoleukodystrophy has increased identification of variants of uncertain significance, accounting for up to 50% of screen-positive cases in some states. These are often associated with borderline biomarker levels, and their natural history remains poorly understood.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>What This Study Adds<\/jats:title>\n                  <jats:p>Screen-positive individuals with VUS had substantially lower rates of disease onset than those with pathogenic variants. Newborn biomarker levels also correlated with variant pathogenicity and disease onset, which may aid future variant classification and risk stratification.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.06.30.26356979","type":"posted-content","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:25:20Z","timestamp":1783009520000},"source":"Crossref","is-referenced-by-count":0,"title":["Disease Outcomes in Boys with\n                  <i>ABCD1<\/i>\n                  Variants Identified by Newborn Screening for X-ALD"],"prefix":"10.64898","author":[{"given":"Cecilie S.","family":"Videbaek","sequence":"first","affiliation":[{"name":"Center for Inherited Metabolic Diseases, Department of Pediatrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-7095","authenticated-orcid":false,"given":"Danielle HJ","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah S.","family":"Hart","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-4968","authenticated-orcid":false,"given":"Razina","family":"Aziz-Bose","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachelle","family":"Purnell-Savoy","sequence":"additional","affiliation":[{"name":"The Moser Center for Leukodystrophies, Kennedy Krieger Institute, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonum","family":"Bharill","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-4331","authenticated-orcid":false,"given":"Ezzat","family":"Hashemi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Orsini","sequence":"additional","affiliation":[{"name":"Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Seeger","sequence":"additional","affiliation":[{"name":"ALD Alliance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"McAuliffe","sequence":"additional","affiliation":[{"name":"ALD Alliance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-8332","authenticated-orcid":false,"given":"Isha","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"MacLean","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Stanford Children\u2019s Health, Palo Alto, CA, USA"},{"name":"Neuroscience Institute, Children\u2019s Hospital of Orange County, Rady Children\u2019s Health, Orange, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Endocrinology, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4116-6990","authenticated-orcid":false,"given":"Ali","family":"Fatemi","sequence":"additional","affiliation":[{"name":"The Moser Center for Leukodystrophies, Kennedy Krieger Institute, Baltimore, MD, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-0293","authenticated-orcid":false,"given":"Julie S.","family":"Cohen","sequence":"additional","affiliation":[{"name":"The Moser Center for Leukodystrophies, Kennedy Krieger Institute, Baltimore, MD, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-8807","authenticated-orcid":false,"given":"Eric","family":"Mallack","sequence":"additional","affiliation":[{"name":"The Moser Center for Leukodystrophies, Kennedy Krieger Institute, Baltimore, MD, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9174-8919","authenticated-orcid":false,"given":"Troy","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Blood and Marrow Transplantation and Cellular Therapy, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-1089","authenticated-orcid":false,"given":"Florian","family":"Eichler","sequence":"additional","affiliation":[{"name":"Center for Rare Neurological Diseases, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-147X","authenticated-orcid":false,"given":"Joshua L.","family":"Bonkowsky","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA"},{"name":"Center for Personalized Medicine, Primary Children\u2019s Hospital, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-1116","authenticated-orcid":false,"given":"Laura","family":"Adang","sequence":"additional","affiliation":[{"name":"Division of Neurology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"},{"name":"Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8220-4183","authenticated-orcid":false,"given":"Zihuai","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA"},{"name":"Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA"},{"name":"Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6091-7879","authenticated-orcid":false,"given":"Allan M.","family":"Lund","sequence":"additional","affiliation":[{"name":"Center for Inherited Metabolic Diseases, Department of Pediatrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0233-9361","authenticated-orcid":false,"given":"Keith P.","family":"van Haren","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA"},{"name":"Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026070600250782000_2026.06.30.26356979v1.1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1210\/endrev\/bnaa013","article-title":"The Changing Face of Adrenoleukodystrophy","volume":"41","year":"2020","journal-title":"Endocr. Rev"},{"key":"2026070600250782000_2026.06.30.26356979v1.2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrendo.2016.90","article-title":"Adrenoleukodystrophy \u2013 neuroendocrine pathogenesis and redefinition of natural history","volume":"12","year":"2016","journal-title":"Nat. Rev. Endocrinol"},{"key":"2026070600250782000_2026.06.30.26356979v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2012.12.007"},{"key":"2026070600250782000_2026.06.30.26356979v1.4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/dmcn.14884","article-title":"Epidemiological, clinical, and genetic characteristics of paediatric genetic white matter disorders in Northern Finland","volume":"63","year":"2021","journal-title":"Dev. Med. Child Neurol"},{"key":"2026070600250782000_2026.06.30.26356979v1.5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s100380200090","article-title":"Epidemiology of X-linked adrenoleukodystrophy in Japan","volume":"47","year":"2002","journal-title":"J. Hum. Genet"},{"key":"2026070600250782000_2026.06.30.26356979v1.6","unstructured":"Leukodystrophy incidence in Germany - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/9286459\/."},{"key":"2026070600250782000_2026.06.30.26356979v1.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2343"},{"key":"2026070600250782000_2026.06.30.26356979v1.8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.braindev.2009.02.002","article-title":"X-linked adrenoleukodystrophy: clinical course and minimal incidence in South Brazil","volume":"32","year":"2010","journal-title":"Brain Dev"},{"key":"2026070600250782000_2026.06.30.26356979v1.9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF00713859","article-title":"X-linked adrenoleukodystrophy: first report of the Italian Study Group","volume":"19","year":"1998","journal-title":"Ital. J. Neurol. Sci"},{"key":"2026070600250782000_2026.06.30.26356979v1.10","doi-asserted-by":"crossref","unstructured":"Videb\u00e6k, C. , Melgaard, L. , Lund, A. M. & Gr\u00f8nborg, S. W . Newborn screening for adrenoleukodystrophy: International experiences and challenges. Mol. Genet. Metab. 140, 107734 (2023).","DOI":"10.1016\/j.ymgme.2023.107734"},{"key":"2026070600250782000_2026.06.30.26356979v1.11","unstructured":"Research, C. for B. E. and. SKYSONA. FDA https:\/\/www.fda.gov\/vaccines-blood-biologics\/skysona (2022)."},{"key":"2026070600250782000_2026.06.30.26356979v1.12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/brain\/awy299","article-title":"Progression of myelopathy in males with adrenoleukodystrophy: towards clinical trial readiness","volume":"142","year":"2019","journal-title":"Brain J. Neurol"},{"key":"2026070600250782000_2026.06.30.26356979v1.13","doi-asserted-by":"crossref","unstructured":"Huffnagel, I. C. et al. Disease progression in women with X-linked adrenoleukodystrophy is slow. Orphanet J. Rare Dis. 14, 30 (2019).","DOI":"10.1186\/s13023-019-1008-6"},{"key":"2026070600250782000_2026.06.30.26356979v1.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt361"},{"key":"2026070600250782000_2026.06.30.26356979v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22114-2"},{"key":"2026070600250782000_2026.06.30.26356979v1.16","doi-asserted-by":"crossref","first-page":"104781","DOI":"10.1016\/j.ebiom.2023.104781","article-title":"Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy","volume":"96","year":"2023","journal-title":"eBioMedicine"},{"key":"2026070600250782000_2026.06.30.26356979v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00513-y"},{"key":"2026070600250782000_2026.06.30.26356979v1.18","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2024.6774"},{"key":"2026070600250782000_2026.06.30.26356979v1.19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy","volume":"22","year":"2022","journal-title":"Expert Opin. Biol. Ther"},{"key":"2026070600250782000_2026.06.30.26356979v1.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201374"},{"key":"2026070600250782000_2026.06.30.26356979v1.21","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12571"},{"key":"2026070600250782000_2026.06.30.26356979v1.22","first-page":"100902","article-title":"High incidence of null variants identified from newborn screening of X-linked adrenoleukodystrophy in Taiwan","volume":"32","year":"2022","journal-title":"Mol. Genet. Metab. Rep"},{"key":"2026070600250782000_2026.06.30.26356979v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2009.03.010"},{"key":"2026070600250782000_2026.06.30.26356979v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.05.001"},{"key":"2026070600250782000_2026.06.30.26356979v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.11.013"},{"key":"2026070600250782000_2026.06.30.26356979v1.26","first-page":"405","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","year":"2015","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet"},{"key":"2026070600250782000_2026.06.30.26356979v1.27","unstructured":"Practice Guidelines. Association for Molecular Pathology https:\/\/www.amp.org\/clinical-practice\/practice-guidelines\/."},{"key":"2026070600250782000_2026.06.30.26356979v1.28","unstructured":"Human Genome Variation Society. https:\/\/www.hgvs.org\/."},{"key":"2026070600250782000_2026.06.30.26356979v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.63995"},{"key":"2026070600250782000_2026.06.30.26356979v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2015.02.002"},{"key":"2026070600250782000_2026.06.30.26356979v1.31","unstructured":"The ABCD1 Variant Database. Adrenoleukodystrophy.info https:\/\/adrenoleukodystrophy.info\/mutations-and-variants-in-abcd1."},{"key":"2026070600250782000_2026.06.30.26356979v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107678"},{"key":"2026070600250782000_2026.06.30.26356979v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12356"},{"key":"2026070600250782000_2026.06.30.26356979v1.34","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1210\/jc.2018-00920","article-title":"Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen","volume":"103","year":"2018","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"2026070600250782000_2026.06.30.26356979v1.35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/ijns10040073","article-title":"Psychological Impact of Presymptomatic X-Linked ALD Diagnosis and Surveillance: A Small Qualitative Study of Patient and Parent Experiences","volume":"10","year":"2024","journal-title":"Int. J. Neonatal Screen"},{"key":"2026070600250782000_2026.06.30.26356979v1.36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-018-0921-4","article-title":"Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme","volume":"13","year":"2018","journal-title":"Orphanet J. Rare Dis"},{"key":"2026070600250782000_2026.06.30.26356979v1.37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamapediatrics.2024.6771","article-title":"Newborn Screening for Adrenoleukodystrophy","volume":"179","year":"2025","journal-title":"JAMA Pediatr"},{"key":"2026070600250782000_2026.06.30.26356979v1.38","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3390\/genes12121930","article-title":"Biochemical Studies in Fibroblasts to Interpret Variants of Unknown Significance in the ABCD1 Gene","volume":"12","year":"2021","journal-title":"Genes"},{"key":"2026070600250782000_2026.06.30.26356979v1.39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/ijns6030062","article-title":"The Clinical Impact of CLIR Tools toward Rapid Resolution of Post-Newborn Screening Confirmatory Testing for X-Linked Adrenoleukodystrophy in California","volume":"6","year":"2020","journal-title":"Int. J. Neonatal Screen"},{"key":"2026070600250782000_2026.06.30.26356979v1.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2026070600250782000_2026.06.30.26356979v1.41","first-page":"1761","article-title":"Adrenoleukodystrophy: a scoring method for brain MR observations","volume":"15","year":"1994","journal-title":"AJNR Am. J. Neuroradiol"},{"key":"2026070600250782000_2026.06.30.26356979v1.42","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1153"},{"key":"2026070600250782000_2026.06.30.26356979v1.43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01307"},{"key":"2026070600250782000_2026.06.30.26356979v1.44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13023-023-02843-x","article-title":"Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden of disease - A population-based study","volume":"18","year":"2023","journal-title":"Orphanet J. Rare Dis"},{"key":"2026070600250782000_2026.06.30.26356979v1.45","doi-asserted-by":"publisher","DOI":"10.1007\/s11373-004-8177-5"},{"key":"2026070600250782000_2026.06.30.26356979v1.46","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19970905)71:4<475::AID-AJMG20>3.0.CO;2-C"},{"key":"2026070600250782000_2026.06.30.26356979v1.47","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/(SICI)1096-8628(19980413)76:5<420::AID-AJMG10>3.0.CO;2-O","article-title":"X-linked adrenoleukodystrophy: the Australasian experience","volume":"76","year":"1998","journal-title":"Am. J. Med. Genet"},{"key":"2026070600250782000_2026.06.30.26356979v1.48","doi-asserted-by":"publisher","DOI":"10.1002\/ana.101"},{"key":"2026070600250782000_2026.06.30.26356979v1.49","unstructured":"Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/32903870\/."},{"key":"2026070600250782000_2026.06.30.26356979v1.50","doi-asserted-by":"crossref","first-page":"e70157","DOI":"10.1002\/jimd.70157","article-title":"The Grey Zone Project: Risk-Based Classification of ABCD1 Variants in X-Linked Adrenoleukodystrophy","volume":"49","year":"2026","journal-title":"J. Inherit. Metab. Dis"},{"key":"2026070600250782000_2026.06.30.26356979v1.51","unstructured":"Criteria Specification Registry. https:\/\/erepo.clinicalgenome.org\/cspec\/ui\/svi\/doc\/1537428517?utm_source=chatgpt.com."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.30.26356979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T07:25:31Z","timestamp":1783322731000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.06.30.26356979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":51,"URL":"https:\/\/doi.org\/10.64898\/2026.06.30.26356979","relation":{},"subject":[],"published":{"date-parts":[[2026,7,2]]},"subtype":"preprint"}}